Aug 24 2009
Curemark Founder and CEO Dr. Joan Fallon delivered the Industry Keynote address at the Third International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on July 14th.
Dr. Fallon's selection to address this cutting-edge conclave is particularly significant, since epigenetics is the study of heritable changes in gene function that occur without a change in the DNA sequence. Presenters at the session showcased many leading researchers, representing Harvard, Columbia and Duke Universities along with MIT and many others.
Dr. Fallon's message focused on Curemark's patented new science, which distinguishes a subset of children with autism. Labeled most recently by the geneticists as "the autisms", the multiple phenotypes which fall on the autism spectrum have yet to be fully delineated on a gene level. Curemark's science provides a route to identify a specific, diagnosable subset of children with autism.
"I'm honored to have been selected, among such distinguished leaders in both academia and industry, to speak at this conference," stated Fallon. "The opportunity to discuss Curemark's science in front of this esteemed group is so important to children with autism around the world as well as to Curemark," she continued.
Curemark is presently conducting a FDA phase III clinical trial for autism.
Social media reshapes children’s diets and body image with alarming consequences